Systematic review of the effectiveness of population screening for colorectal cancer

New Zealand Medical Journal

Volumn 120, Issue 1258, 2007, Pages

  Kerr, Jane ^a   Day, Peter ^a   Broadstock, Marita ^a   Weir, Robert ^a   Bidwell, Susan ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

GUAIAC;

CANCER MORTALITY; CANCER SCREENING; CLINICAL TRIAL; COCHRANE LIBRARY; COLONOSCOPY; COLORECTAL CANCER; DATA ANALYSIS; EMBASE; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; MASS SCREENING; MEDLINE; META ANALYSIS; OCCULT BLOOD; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; AGED; COLORECTAL TUMOR; MIDDLE AGED; MORTALITY;

AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; HUMANS; MASS SCREENING; MIDDLE AGED; OCCULT BLOOD; SIGMOIDOSCOPY;

EID: 34547422236     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Minister of Health. The New Zealand cancer control strategy. Wellington: Ministry of Health and the New Zealand Cancer Control Trust; 2003.
2. New Zealand Health Information Service. Cancer: New registrations and deaths 2000. Wellington: Ministry of Health; 2004.
3. Working Party on Screening for Colorectal Cancer. Population screening for colorectal cancer. Wellington: National Health Committee; 1998.
4. Anonymous. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer. N Z Med J. 1999; 112:4-6.
5. Kerr J, Broadstock M, Day P, Hogan S. Effectiveness and cost-effectiveness of population screening for colorectal cancer: A systematic review of the literature. NZHTA Report. 2005;8(1):1-186.
6. Jackson R. The GATE approach: Teaching and learning evidence-based practice with pictures. 2005 [cited 2005 Dec 9] http://www.health.auckland.ac.nz/population-health/ epidemiology-biostats/epig/updatedGATESicily.pdf
7. Law MR. The number needed to screen-an adaptation of the number needed to treat. J Med Screen. 2001;8:114-5.
8. Altman DG. Confidence intervals for the number needed to treat. BMJ. 1998;317:1309-12.
9. StataCorp. Stata statistical software: Release 7.0. College Station, TX: Stata Corporation; 2001.
10. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999;91:434-7.
11. Mandel JS, Church TF, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Eng J Med. 2000;343:1603-7.
12. Scholefield JH, Moss SM. Faecal occult blood screening for colorectal cancer. J Med Screen 2002;9:54-5.
13. Kronborg O, Jorgensen OD, Fenger C, Rasmussen M. Randomized study of biennial screening with a faecal occult blood test: Results after nine screening rounds. Scand J Gastroenterol 2004;39:846-51.
14. Kronborg O, Fenger C, Olsen J, et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test Lancet. 1996;348:1467-71.
15. Jorgensen OD, Kronborg O, Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: Results after 13 years and seven biennial screening rounds. Gut. 2002;50:29-32.
16. Zheng S, Chen K, Liu X, et al. Cluster randomization trial of sequence mass screening for colorectal cancer. Dis Colon Rectum. 2003;46:51-8.
17. U. K. Flexible Sigmoidoscopy Screening Trial Investigators. Single flexible sigmoidoscopy screening to prevent colorectal cancer: Baseline findings of a UK multicentre randomised trial. Lancet. 2002;359:1291-300.
18. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy" - SCORE. J Natl Cancer Inst. 2002;94:1763-72.
19. Schoen RE, Pinsky PF, Weissfeld JL, et al. Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA. 2003;290:41-8.
20. Rasmussen M, Kronborg O, Fenger C, Jorgensen OD. Possible advantages and drawbacks of adding flexible sigmoidoscopy to hemoccult-II in screening for colorectal cancer. A randomized study. Scand J Gastroenterol. 1999;34:73-8.
21. Young GP, St John DJ, Winawer SJ, et al. Choice of fecal occult blood tests for colorectal cancer screening: Recommendations based on performance characteristics in population studies: A WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J Gastroenterol. 2002;97:2499-507.
22. Winawer SJ. Colorectal cancer screening comes of age. N Eng J Med. 1993;328:1416-7.
23. Allison JE. Screening for colorectal cancer 2003: Is there still a role for the FOBT? Tech Gastrointest Endosc. 2003;5:127-33.
24. Towler B, Irwig L, Glasziou P, et al. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ. 1998;317:559-65.
25. Kewenter J, Brevinge H, Engaras B, et al. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol. 1994;29:468-73.
26. Thiis-Evensen E, Hoff GS, Sauar J, et al. The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. Am J Gastroenterol. 2001;96:1901-7.
27. Gondal G, Grotmol T, Hofstad B, et al. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: Baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-42.
28. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7.